Literature DB >> 19262594

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells.

D K Hiwase, D L White, V A Saunders, S Kumar, J V Melo, T P Hughes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19262594     DOI： 10.1038/leu.2009.45

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  6 in total

1.  Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia.

Authors:  L Schafranek; E Nievergall; J A Powell; D K Hiwase; T Leclercq; T P Hughes; D L White
Journal:  Leukemia       Date:  2014-05-12       Impact factor: 11.528

2.  Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors.

Authors:  Y Minami; A Abe; M Minami; K Kitamura; J Hiraga; S Mizuno; K Ymamoto; M Sawa; Y Inagaki; K Miyamura; T Naoe
Journal:  Leukemia       Date:  2012-03-19       Impact factor: 11.528

3.  Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.

Authors:  Daniel B Lipka; Marie-Christine Wagner; Marek Dziadosz; Tina Schnöder; Florian Heidel; Mirle Schemionek; Junia V Melo; Thomas Kindler; Carsten Müller-Tidow; Steffen Koschmieder; Thomas Fischer
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

4.  Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.

Authors:  Thomas O'Hare; Christopher A Eide; Anupriya Agarwal; Lauren T Adrian; Matthew S Zabriskie; Ryan J Mackenzie; Dorian H Latocha; Kara J Johnson; Huihong You; Jenny Luo; Steven M Riddle; Bryan D Marks; Kurt W Vogel; Dennis R Koop; John Apgar; Jeffrey W Tyner; Michael W Deininger; Brian J Druker
Journal:  Cancer Res       Date:  2013-04-10       Impact factor: 12.701

5.  Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation.

Authors:  Hui-Chuan Yu; Chen-Si Lin; Wei-Tien Tai; Chun-Yu Liu; Chung-Wai Shiau; Kuen-Feng Chen
Journal:  J Biol Chem       Date:  2013-05-15       Impact factor: 5.157

6.  Kinase inhibitor therapy in CML: it's what's inside that counts.

Authors:  Christopher A Eide; Brian J Druker; Thomas O'Hare
Journal:  Oncotarget       Date:  2013-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.